Enhancement of immune responses to newcastle disease and avian influenza vaccines by GM-CSF and FliC as biological adjuvants in SPF chickens.
Sun Wenying W, Wang Jingming J, Zhang Lin L, Xue Zhiqiang Z et al.
Avian Influenza (AI) and Newcastle Disease (ND) are two acute, highly contagious infectious diseases that frequently affect poultry production and result in severe economic damage. Although vaccination is the primary means of controlling AI and ND outbreaks, currently available vaccines typically suffer from weak immunogenicity and a delayed onset of protective immunity. Therefore, it is crucial to identify suitable adjuvants to enhance the effectiveness of vaccines. In this study, Hemagglutinin (HA), granulocyte-macrophage colony stimulating factor (GM-CSF), and flagellin (FliC) were expressed in E. coli prokaryotic expression systems, SPF chickens were inoculated with HA vaccine and two types of ND-AI bivalent vaccines with chicken GM-CSF (chGM-CSF) and FliC as adjuvants separately or combined. The impact of these adjuvants on immune responses was evaluated through multiple indicators: serum antibody levels against NDV and AIV; percentages of CD4⁺ T lymphocytes, CD8⁺ T lymphocytes, and B cells among leukocytes; serum concentrations of the cytokines IL‑4, IL‑1β, IFN‑γ, and GM‑CSF; and the mRNA expression of IL‑4, IL‑6, IL‑1β, TNF‑α, IFN‑γ, and GM‑CSF in both leukocytes and spleen tissue. The findings demonstrated that vaccines formulated with combined adjuvants induced stronger humoral, cellular, and inflammatory immune responses, and these responses lasted longer than those elicited by vaccines containing a single adjuvant or no adjuvant. At necropsy, no obvious gross lesions were observed in the bursa, spleen, thymus, or lungs of vaccinated chickens, consistent with hematoxylin and eosin (HE) staining, which revealed no inflammatory infiltration, tissue necrosis, or structural destruction in these tissues, indicating favorable tissue safety of the tested vaccine formulations. Notably, this study was performed in SPF chickens under laboratory conditions; therefore, further validation in field settings, including challenge testing and gross lesion assessment, is warranted. Collectively, this research lays a foundation for the future use of biological adjuvants in vaccine development.